Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Revolution Medicines, Inc. - Common Stock
(NQ:
RVMD
)
95.98
-0.76 (-0.79%)
Official Closing Price
Updated: 4:15 PM EST, Feb 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revolution Medicines, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
↗
June 08, 2024
Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder
Via
InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
↗
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024
↗
May 08, 2024
RVMD stock results show that Revolution Medicines beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Top 3 Health Care Stocks That May Collapse In Q2
↗
April 12, 2024
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
April 10, 2024
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.
Via
Benzinga
What's Going On With Revolution Medicines Stock?
↗
April 10, 2024
Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The...
Via
Benzinga
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
↗
April 10, 2024
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.
Via
Benzinga
Topics
Stocks
Revolution Medicines Inc. (NASDAQ: RVMD) Climbs to New 52-Week High
April 10, 2024
Via
Investor Brand Network
Morgan Stanley Maintains Equal-Weight Rating for Revolution Medicines: Here's What You Need To Know
↗
March 08, 2024
Via
Benzinga
Uncovering Noteworthy Technical Analysis Findings for REVOLUTION MEDICINES INC (NASDAQ:RVMD).
↗
February 01, 2024
A technical analysis of REVOLUTION MEDICINES INC.
Via
Chartmill
What 6 Analyst Ratings Have To Say About Revolution Medicines
↗
November 07, 2023
Via
Benzinga
Earnings Scheduled For November 6, 2023
↗
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
Preview: Revolution Medicines's Earnings
↗
November 03, 2023
Via
Benzinga
Why Revolution Medicines Stock Is Crashing Today
↗
October 23, 2023
Investors were disappointed by Revolution Medicines' data, presented at ESMO.
Via
The Motley Fool
Earnings Scheduled For February 26, 2024
↗
February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Via
Benzinga
Revolution Medicines's Earnings: A Preview
↗
February 23, 2024
Via
Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
↗
December 15, 2023
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via
InvestorPlace
3 Biotech Stocks That Could Boom or Bust by 2025
↗
November 16, 2023
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.
Via
InvestorPlace
Cancer Player Revolution Medicines Gets Bullish Rating: Here's Details
↗
November 16, 2023
Raymond James initiated coverage on Revolution Medicines Inc (NASDAQ: RVMD), noting that the October readout of RMC-6236 was compelling compared to historical SoC.
Via
Benzinga
Crude Oil Falls Sharply; Apollomics Shares Plunge
↗
October 23, 2023
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded down 0.19% to 33,062.85 while the NASDAQ rose 0.80% to 13,088.09. The S&P...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 23, 2023
Via
Benzinga
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
October 23, 2023
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.
Via
Benzinga
Nasdaq Turns Higher; Akumin Shares Jump
↗
October 23, 2023
U.S. stocks pared losses midway through trading, with the Nasdaq Composite gaining over 60 points on Monday. The Dow traded down 0.01% to 33,126.50 while the NASDAQ rose 0.54% to 13,054.00. The S&P 500...
Via
Benzinga
Topics
Stocks
FMC, Li-Cycle Holdings, Okta And Other Big Stocks Moving Lower On Monday
↗
October 23, 2023
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Topics
Stocks
Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment
↗
October 23, 2023
The results were "at best, in line" with expectations for lung and pancreatic cancer treatment.
Via
Investor's Business Daily
Dow Falls Over 100 Points; Chicago Fed National Activity Index Increases In September
↗
October 23, 2023
U.S. stocks traded lower this morning, with the Dow Jones index falling over 100 points on Monday. Following the market opening Monday, The Dow traded down 0.41% to 32,991.58 while the NASDAQ fell...
Via
Benzinga
Topics
Economy
Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 23, 2023
Via
Benzinga
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
↗
October 16, 2023
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday
↗
October 16, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session.
Via
Benzinga
Topics
Stocks
Why Shares of Revolution Medicines Were Popping on Friday
↗
October 13, 2023
The company released positive phase 1/1b trial data on two cancer therapies.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.